Literature DB >> 32291805

Clinical guidelines for interstitial cystitis/bladder pain syndrome.

Yukio Homma1, Yoshiyuki Akiyama2, Hikaru Tomoe3, Akira Furuta4, Tomohiro Ueda5, Daichi Maeda6, Alex Tl Lin7, Hann-Chorng Kuo8, Ming-Huei Lee9, Seung-June Oh10, Joon Chul Kim11, Kyu-Sung Lee12.   

Abstract

The clinical guidelines for interstitial cystitis and related symptomatic conditions were revised by updating our previous guidelines. The current guidelines define interstitial cystitis/bladder pain syndrome as a condition with chronic pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by other urinary symptoms, such as persistent urge to void or urinary frequency in the absence of confusable diseases. The characteristic symptom complex is collectively referred as hypersensitive bladder symptoms. Interstitial cystitis/bladder pain syndrome is divided into Hunner-type interstitial cystitis and bladder pain syndrome; Hunner-type interstitial cystitis and bladder pain syndrome represent interstitial cystitis/bladder pain syndrome with Hunner lesions and interstitial cystitis/bladder pain syndrome without Hunner lesions, respectively. So-called non-Hunner-type interstitial cystitis featured by glomerulations or bladder bleeding after distension is included in bladder pain syndrome. The symptoms are virtually indistinguishable between Hunner-type interstitial cystitis and bladder pain syndrome; however, Hunner-type interstitial cystitis and bladder pain syndrome should be considered as a separate entity of disorder. Histopathology totally differs between Hunner-type interstitial cystitis and bladder pain syndrome; Hunner-type interstitial cystitis is associated with severe inflammation of the urinary bladder accompanied by lymphoplasmacytic infiltration and urothelial denudation, whereas bladder pain syndrome shows little pathological changes in the bladder. Pathophysiology would also differ between Hunner-type interstitial cystitis and bladder pain syndrome, involving interaction of multiple factors, such as inflammation, autoimmunity, infection, exogenous substances, urothelial dysfunction, neural hyperactivity and extrabladder disorders. The patients should be treated differently based on the diagnosis of Hunner-type interstitial cystitis or bladder pain syndrome, which requires cystoscopy to determine the presence or absence Hunner lesions. Clinical studies are to be designed to analyze outcomes separately for Hunner-type interstitial cystitis and bladder pain syndrome.
© 2020 The Japanese Urological Association.

Entities:  

Keywords:  Hunner lesions; bladder pain syndrome; guidelines; hypersensitive bladder symptoms; interstitial cystitis

Mesh:

Year:  2020        PMID: 32291805     DOI: 10.1111/iju.14234

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  34 in total

1.  The impact of Hunner lesion-type interstitial cystitis/bladder pain syndrome on health-related quality of life and the effects of transurethral ablation.

Authors:  Kwang Jin Ko; Jihyun Lim; Jiwoong Yu; Danbee Kang; Juhee Cho; Kyu-Sung Lee
Journal:  Qual Life Res       Date:  2022-07-23       Impact factor: 3.440

2.  [Urodynamic and histological evaluation of cyclophosphamide-induced bladder pain syndrome in SD rats].

Authors:  L Zhu; W Y Zhang; K X Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

Review 3.  The Role of Urinary VEGF in Observational Studies of BPS/IC Patients: A Systematic Review.

Authors:  Pedro Abreu-Mendes; Aurora Costa; Ana Charrua; Rui Almeida Pinto; Francisco Cruz
Journal:  Diagnostics (Basel)       Date:  2022-04-20

4.  Autoimmunity to urothelial antigen causes bladder inflammation, pelvic pain, and voiding dysfunction: a novel animal model for Hunner-type interstitial cystitis.

Authors:  Yoshiyuki Akiyama; Jian-Rong Yao; Karl J Kreder; Michael A O'Donnell; Susan K Lutgendorf; Dan Lyu; Daichi Maeda; Haruki Kume; Yukio Homma; Yi Luo
Journal:  Am J Physiol Renal Physiol       Date:  2020-12-14

5.  Multimodal Single-Cell Analyses Outline the Immune Microenvironment and Therapeutic Effectors of Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Fei Su; Wei Zhang; Lingfeng Meng; Wei Zhang; Xiaodong Liu; Xiaorui Liu; Meng Chen; Yaoguang Zhang; Fei Xiao
Journal:  Adv Sci (Weinh)       Date:  2022-04-25       Impact factor: 17.521

6.  Effects of human Muse cells on bladder inflammation, overactivity, and nociception in a chemically induced Hunner-type interstitial cystitis-like rat model.

Authors:  Akira Furuta; Yasumasa Kuroda; Tokunori Yamamoto; Shin Egawa; Mari Dezawa; Naoki Yoshimura
Journal:  Int Urogynecol J       Date:  2022-03-25       Impact factor: 1.932

7.  Relationship between the frequency of electrocautery of Hunner lesions and changes in bladder capacity in patients with Hunner type interstitial cystitis.

Authors:  Yoshiyuki Akiyama; Masayoshi Zaitsu; Daiji Watanabe; Itsuki Yoshimura; Aya Niimi; Akira Nomiya; Yuta Yamada; Yusuke Sato; Masaki Nakamura; Taketo Kawai; Daisuke Yamada; Motofumi Suzuki; Haruki Kume; Yukio Homma
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

8.  Current Understanding and Future Perspectives of Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Tomohiro Ueda; Philip M Hanno; Ryoichi Saito; Jane M Meijlink; Naoki Yoshimura
Journal:  Int Neurourol J       Date:  2021-06-30       Impact factor: 2.835

Review 9.  Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome.

Authors:  Hung-Yu Lin; Jian-He Lu; Shu-Mien Chuang; Kuang-Shun Chueh; Tai-Jui Juan; Yi-Chang Liu; Yung-Shun Juan
Journal:  Diagnostics (Basel)       Date:  2021-12-29

Review 10.  Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome with and without Hunner Lesion: A Review and Future Perspectives.

Authors:  Yoshiyuki Akiyama
Journal:  Diagnostics (Basel)       Date:  2021-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.